The company stated that CagriSema demonstrated 23% weight loss in people with obesity, failing to meet its primary endpoint.
Novo Nordisk AS (NVO) shares fell more than 10% in Monday’s pre-market trade after the company announced headline results from Redefine 4, an open-label phase 3 trial.
Add Asianet Newsable as a Preferred Source
Novo Nordisk stated that CagriSema demonstrated 23% weight loss in people with obesity, but it failed to meet its primary endpoint.
Retail sentiment on Stocktwits around Novo Nordisk trended in the ‘extremely bearish’ territory at the time of writing.
Get updates to this story developing directly on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
